GH PEPTIDES MONOGRAPH
CJC-1295 Research Monograph
Long-acting GHRH analogue with DAC — endocrine pharmacology research
CJC-1295 is a synthetic 30-amino-acid analogue of growth hormone releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that binds plasma albumin. The albumin-binding modification dramatically extends in-vivo half-life relative to native GHRH(1-29), making the compound suitable for sustained-elevation GH-axis research.
Background: native GHRH and the DAC modification
Native GHRH(1-29) — the active fragment corresponding to the research peptide sermorelin — has a plasma half-life of 5–10 minutes. CJC-1295 incorporates a maleimidopropionyl-DAC modification at the C-terminus that covalently couples the peptide to circulating albumin, extending in-vivo persistence by orders of magnitude.
Sequence and structure
The published sequence is Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Gln-Cys(Maleimidopropionyl)-NH2. Molecular weight is 3367.9 g/mol. The C-terminal cysteine carries the DAC linker.
Primary research literature
The foundational pharmacokinetic characterisation by Teichman et al. (2006, JCEM) established CJC-1295's sustained-release profile in healthy adult research subjects. Subsequent literature has explored its use in sustained GH-elevation research designs.
Comparison with sermorelin
Sermorelin corresponds to native GHRH(1-29) without the DAC modification. It produces sharp pulse-shaped GH-release patterns suitable for pulsatile-research designs. CJC-1295 produces sustained-elevation patterns suitable for chronic-administration research designs. See the VESPER /compare/cjc-1295-vs-sermorelin page for direct comparison.
Storage, reconstitution, and handling
Lyophilised CJC-1295 is stable for months at −20°C in its sealed vial. After reconstitution, store at 2–8°C and use within 7 days.
Quality and verification
VESPER CJC-1295 is supplied as a 2mg lyophilised vial at ≥99.5% HPLC purity, with sequence identity confirmed by mass spectrometry on every batch.
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Gln-Cys(Maleimidopropionyl)-NH2
Molecular weight
3367.9 g/mol
CAS
863288-34-0
Purity
≥99.5%
Storage
−20°C, protected from light
Vial format
2mg / vial
Frequently asked
What is the DAC in CJC-1295?
DAC stands for Drug Affinity Complex — a maleimidopropionyl modification at the C-terminal cysteine that covalently couples the peptide to circulating albumin to extend in-vivo half-life.
How does CJC-1295 differ from sermorelin?
Sermorelin is native GHRH(1-29) without the DAC modification — short half-life, pulsatile release. CJC-1295 has the DAC and produces sustained release over days.
What is the molecular weight of CJC-1295?
3367.9 g/mol for the DAC-modified 30-amino-acid peptide.
⚠ For research use only. Not for human consumption.